{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:55:56Z","timestamp":1775325356746,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T00:00:00Z","timestamp":1545264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T00:00:00Z","timestamp":1545264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40744-018-0133-3","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T23:47:47Z","timestamp":1545263267000},"page":"5-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Review for Physician Assistants and Nurse Practitioners on the Considerations for Diagnosing and Treating Psoriatic Arthritis"],"prefix":"10.1007","volume":"6","author":[{"given":"Antonio","family":"Giannelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,20]]},"reference":[{"key":"133_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1529-8019.2008.01215.x","volume":"22","author":"DD Gladman","year":"2009","unstructured":"Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22:40\u201355.","journal-title":"Dermatol Ther"},{"key":"133_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3899\/jrheum.080691","volume":"36","author":"FC Wilson","year":"2009","unstructured":"Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36:361\u20137.","journal-title":"J Rheumatol"},{"key":"133_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section\u00a02. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851\u201364.","journal-title":"J Am Acad Dermatol"},{"key":"133_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4081\/reumatismo.2012.66","volume":"64","author":"M Catanoso","year":"2012","unstructured":"Catanoso M, Pipitone N, Salvarani C. Epidemiology of psoriatic arthritis. Reumatismo. 2012;64:66\u201370.","journal-title":"Reumatismo."},{"key":"133_CR5","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64 Suppl 2","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14\u20137.","journal-title":"Ann Rheum Dis"},{"key":"133_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11926-015-0517-0","volume":"17","author":"LC Coates","year":"2015","unstructured":"Coates LC, Helliwell PS. Treat to target in psoriatic arthritis\u2014evidence, target, research agenda. Curr Rheumatol Rep. 2015;17:517.","journal-title":"Curr Rheumatol Rep"},{"key":"133_CR7","doi-asserted-by":"publisher","first-page":"e0123582","DOI":"10.1371\/journal.pone.0123582","volume":"10","author":"B Michelsen","year":"2015","unstructured":"Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One. 2015;10:e0123582.","journal-title":"PLoS One"},{"key":"133_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","volume":"51","author":"CF Rosen","year":"2012","unstructured":"Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012;51:571\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"133_CR9","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"133_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:423\u201341.","journal-title":"Drugs."},{"key":"133_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.berh.2014.10.010","volume":"28","author":"DD O\u2019Rielly","year":"2014","unstructured":"O\u2019Rielly DD, Rahman P. Genetics of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2014;28:673\u201385.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"133_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2340\/00015555-1833","volume":"94","author":"K de Vlam","year":"2014","unstructured":"de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014;94:627\u201334.","journal-title":"Acta Derm Venereol"},{"key":"133_CR13","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.3899\/jrheum.080668","volume":"35","author":"I Olivieri","year":"2008","unstructured":"Olivieri I, Padula A, D\u2019Angelo S, Scarpa R. Role of trauma in psoriatic arthritis. J Rheumatol. 2008;35:2085\u20137.","journal-title":"J Rheumatol"},{"key":"133_CR14","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060\u201371.","journal-title":"Arthritis Rheumatol."},{"key":"133_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3899\/jrheum.080668","volume":"35","author":"I Olivieri","year":"2008","unstructured":"Olivieri I, D\u2019Angelo S, Padula A, Palazzi C. The challenge of early diagnosis of psoriatic arthritis. J Rheumatol. 2008;35:3\u20135.","journal-title":"J Rheumatol"},{"key":"133_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/247553031016a00403","volume":"16","author":"K Busse","year":"2010","unstructured":"Busse K, Liao W. Which psoriasis patients develop psoriatic arthritis? Psoriasis Forum. 2010;16:17\u201325.","journal-title":"Psoriasis Forum."},{"key":"133_CR17","first-page":"S26","volume":"33","author":"ML Acosta Felquer","year":"2015","unstructured":"Acosta Felquer ML, FitzGerald O. Peripheral joint involvement in psoriatic arthritis patients. Clin Exp Rheumatol. 2015;33:S26\u201330.","journal-title":"Clin Exp Rheumatol"},{"key":"133_CR18","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3899\/jrheum.141545","volume":"42","author":"A Haddad","year":"2015","unstructured":"Haddad A, Johnson SR, Somaily M, et al. Psoriatic arthritis mutilans: clinical and radiographic criteria: a systematic review. J Rheumatol. 2015;42:1432\u20138.","journal-title":"J Rheumatol."},{"key":"133_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.rdc.2015.07.003","volume":"41","author":"DD Gladman","year":"2015","unstructured":"Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:569\u201379.","journal-title":"Rheum Dis Clin North Am"},{"key":"133_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17:65\u201370.","journal-title":"Clin Med (Lond)."},{"key":"133_CR21","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/acr.23174","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek A, Li S, Chandran V, Gladman DD. Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome. Arthritis Care Res (Hoboken). 2017;69:1685\u201391.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"133_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.semarthrit.2013.04.005","volume":"43","author":"LI Sakkas","year":"2013","unstructured":"Sakkas LI, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013;43:325\u201334.","journal-title":"Semin Arthritis Rheum"},{"key":"133_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2017.12.008","volume":"48","author":"GS Kaeley","year":"2018","unstructured":"Kaeley GS, Eder L, Aydin SZ, Gutierrez M, Bakewell C. Enthesitis: a hallmark of psoriatic arthritis. Semin Arthritis Rheum. 2018;48:35\u201343.","journal-title":"Semin Arthritis Rheum"},{"key":"133_CR24","first-page":"5","volume":"15","author":"M Mok","year":"2010","unstructured":"Mok M. The clinical spectrum and diagnosis of psoriatic arthropathy. Hong Kong Med Diary. 2010;15:5\u20137.","journal-title":"Hong Kong Med Diary."},{"key":"133_CR25","first-page":"1217","volume":"34","author":"I Olivieri","year":"2007","unstructured":"Olivieri I, Padula A, Scarano E, Scarpa R. Dactylitis or \u201csausage-shaped\u201d digit. J Rheumatol. 2007;34:1217\u201322.","journal-title":"J Rheumatol"},{"key":"133_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/ard.57.1.61a","volume":"57","author":"A Padula","year":"1998","unstructured":"Padula A, Salvarani C, Barozzi L, et al. Dactylitis also involving the synovial sheaths in the palm of the hand: two more cases studied by magnetic resonance imaging. Ann Rheum Dis. 1998;57:61\u20132.","journal-title":"Ann Rheum Dis"},{"key":"133_CR27","first-page":"1626","volume":"30","author":"I Olivieri","year":"2003","unstructured":"Olivieri I, Scarano E, Padula A, Giasi V. Dactylitis of the thumb extending to the radial bursa. J Rheumatol. 2003;30:1626\u20137.","journal-title":"J Rheumatol"},{"key":"133_CR28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"133_CR29","doi-asserted-by":"crossref","unstructured":"Kaeley GS, Eder L, Aydin SZ, Gutierrez M, Bakewell C. Dactylitis: a hallmark of psoriatic arthritis. Semin Arthritis Rheum. 2018;48:35\u201343.","DOI":"10.1016\/j.semarthrit.2017.12.008"},{"key":"133_CR30","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1590\/S0482-50042012000400012","volume":"52","author":"DG Ruiz","year":"2012","unstructured":"Ruiz DG, Azevedo MN, Santos OL. Psoriatic arthritis: a clinical entity distinct from psoriasis? Rev Bras Reumatol. 2012;52:630\u20138.","journal-title":"Rev Bras Reumatol."},{"key":"133_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/art.24172","volume":"61","author":"FC Wilson","year":"2009","unstructured":"Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233\u20139.","journal-title":"Arthritis Rheum"},{"key":"133_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.semarthrit.2014.05.002","volume":"44","author":"MK Sandre","year":"2014","unstructured":"Sandre MK, Rohekar S. Psoriatic arthritis and nail changes: exploring the relationship. Semin Arthritis Rheum. 2014;44:162\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"133_CR33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ad.2015.02.005","volume":"106","author":"I Raposo","year":"2015","unstructured":"Raposo I, Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr. 2015;106:452\u20137.","journal-title":"Actas Dermosifiliogr."},{"key":"133_CR34","first-page":"iii22-4","volume":"65 Suppl 3","author":"DD Gladman","year":"2006","unstructured":"Gladman DD. Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? Ann Rheum Dis. 2006;65 Suppl 3:iii22-4.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"133_CR35","doi-asserted-by":"crossref","first-page":"ii69","DOI":"10.1136\/ard.2004.031690","volume":"64","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Behrens F, Boehncke WH, et al. Discussion: assessment of psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl II):ii69\u201373.","journal-title":"Ann Rheum Dis"},{"key":"133_CR36","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/acr.23460","volume":"70","author":"LC Coates","year":"2018","unstructured":"Coates LC, Tillett W, Shaddick G, Pincus T, Kavanaugh A, Helliwell PS. Value of the routine assessment of patient index data 3 in patients with psoriatic arthritis: results from a tight-control clinical trial and an observational cohort. Arthritis Care Res (Hoboken). 2018;70:1198\u2013205.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"133_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/BOR.0000000000000232","volume":"28","author":"A Paine","year":"2016","unstructured":"Paine A, Ritchlin C. Bone remodeling in psoriasis and psoriatic arthritis: an update. Curr Opin Rheumatol. 2016;28:66\u201375.","journal-title":"Curr Opin Rheumatol"},{"key":"133_CR38","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10067-015-2961-7","volume":"34","author":"SK Raychaudhuri","year":"2015","unstructured":"Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol. 2015;34:1019\u201323.","journal-title":"Clin Rheumatol"},{"key":"133_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/acr.20104","volume":"62","author":"AA Saad","year":"2010","unstructured":"Saad AA, Ashcroft DM, Watson KD, et al. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken). 2010;62:345\u201353.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"133_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499\u2013510.","journal-title":"Ann Rheum Dis"},{"key":"133_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4\u201312.","journal-title":"Ann Rheum Dis"},{"key":"133_CR42","first-page":"187","volume":"68","author":"KK Raja Babu","year":"2002","unstructured":"Raja Babu KK. Pharmacological interventions for psoriatic arthritis: present and future. Indian J Dermatol Venereol Leprol. 2002;68:187\u201397.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"133_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3899\/jrheum.150642","volume":"93","author":"O Addimanda","year":"2015","unstructured":"Addimanda O, Possemato N, Caruso A, Pipitone N, Salvarani C. The role of tumor necrosis factor-\u03b1 blockers in psoriatic disease. Therapeutic options in psoriatic arthritis. J Rheumatol Suppl. 2015;93:73\u20138.","journal-title":"J Rheumatol Suppl"},{"key":"133_CR44","first-page":"S104","volume":"33","author":"P Mease","year":"2015","unstructured":"Mease P. A short history of biological therapy for psoriatic arthritis. Clin Exp Rheumatol. 2015;33:S104\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"133_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40744-017-0066-2","volume":"4","author":"M Garrido-Cumbrera","year":"2017","unstructured":"Garrido-Cumbrera M, Hillmann O, Mahapatra R, et al. Improving the management of psoriatic arthritis and axial spondyloarthritis: roundtable discussions with healthcare professionals and patients. Rheumatol Ther. 2017;4:219\u201331.","journal-title":"Rheumatol Ther."},{"key":"133_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13317-013-0057-4","volume":"5","author":"B Marinoni","year":"2014","unstructured":"Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights. 2014;5:9\u201319.","journal-title":"Auto Immun Highlights."},{"key":"133_CR47","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1\u00a0year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780\u20139.","journal-title":"Lancet"},{"key":"133_CR48","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjd.12632","volume":"170","author":"P Rich","year":"2014","unstructured":"Rich P, Bourcier M, Sofen H, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170:398\u2013407.","journal-title":"Br J Dermatol"},{"key":"133_CR49","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000\u20136.","journal-title":"Ann Rheum Dis"},{"key":"133_CR50","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990\u20139.","journal-title":"Ann Rheum Dis"},{"key":"133_CR51","unstructured":"Cosentyx (secukinumab) [prescribing information]. Novartis, East Hanover. 2018."},{"key":"133_CR52","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534\u201348.","journal-title":"N Engl J Med"},{"key":"133_CR53","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76:1070\u20137.","journal-title":"Ann Rheum Dis"},{"key":"133_CR54","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1177\/2040622315582354","volume":"6","author":"EJ Kang","year":"2015","unstructured":"Kang EJ, Kavanaugh A. Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis. 2015;6:194\u2013203.","journal-title":"Ther Adv Chronic Dis."},{"key":"133_CR55","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065\u201373.","journal-title":"Ann Rheum Dis"},{"key":"133_CR56","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020\u20136.","journal-title":"Ann Rheum Dis"},{"key":"133_CR57","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","volume":"74","author":"P Rich","year":"2016","unstructured":"Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74:134\u201342.","journal-title":"J Am Acad Dermatol"},{"key":"133_CR58","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.4103\/0976-500X.120943","volume":"4","author":"F Ursini","year":"2013","unstructured":"Ursini F, Naty S, Russo E, Grembiale RD. Abatacept in psoriatic arthritis: case report and short review. J Pharmacol Pharmacother. 2013;4:S29\u201332.","journal-title":"J Pharmacol Pharmacother."},{"key":"133_CR59","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76:1550\u20138.","journal-title":"Ann Rheum Dis"},{"key":"133_CR60","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1136\/ard.2010.145946","volume":"70","author":"IH Song","year":"2011","unstructured":"Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011;70:1108\u201310.","journal-title":"Ann Rheum Dis"},{"key":"133_CR61","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525\u201336.","journal-title":"N Engl J Med"},{"issue":"79\u201387","key":"133_CR62","first-page":"e1","volume":"77","author":"JF Merola","year":"2017","unstructured":"Merola JF, Elewski B, Tatulych S, Lan S, Tallman A, Kaur M. Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2017;77(79\u201387):e1.","journal-title":"J Am Acad Dermatol"},{"key":"133_CR63","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76:1340\u20137.","journal-title":"Ann Rheum Dis"},{"key":"133_CR64","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279\u201389.","journal-title":"Arthritis Rheum"},{"key":"133_CR65","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48\u201355.","journal-title":"Ann Rheum Dis"},{"key":"133_CR66","doi-asserted-by":"publisher","first-page":"c147","DOI":"10.1136\/bmj.c147","volume":"340","author":"W Sterry","year":"2010","unstructured":"Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.","journal-title":"BMJ"},{"key":"133_CR67","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976\u201386.","journal-title":"Arthritis Rheum"},{"key":"133_CR68","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.40226","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Husni ME, Harrison DD, et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheumatol. 2017;69:2151\u201361.","journal-title":"Arthritis Rheumatol."},{"key":"133_CR69","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150\u20137.","journal-title":"Ann Rheum Dis"},{"key":"133_CR70","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389:2317\u201327.","journal-title":"Lancet"},{"key":"133_CR71","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137\u201346.","journal-title":"Lancet"},{"key":"133_CR72","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/jdv.12553","volume":"29","author":"D Thaci","year":"2015","unstructured":"Thaci D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015;29:353\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"133_CR73","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/bjd.12060","volume":"168","author":"JP Ortonne","year":"2013","unstructured":"Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168:1080\u20137.","journal-title":"Br J Dermatol"},{"key":"133_CR74","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367\u201374.","journal-title":"Lancet"},{"key":"133_CR75","unstructured":"Reich K, Arenberger P, Mrowietz U, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 1.5-year results from the TRANSFIGURE study. In: Presented at the American Academy of Dermatology annual meeting, Orlando, 3\u20137 Mar 2017."},{"key":"133_CR76","unstructured":"Dermnet. Psoriatic arthritis photo. http:\/\/www.dermnet.com\/images\/Psoriatic-Arthritis\/picture\/7097. Cited 9 Dec 2016."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-018-0133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-018-0133-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-018-0133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:06:41Z","timestamp":1775322401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-018-0133-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,20]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s40744-018-0133-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,20]]},"assertion":[{"value":"24 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}